BICARA THERAPEUTICS
Bicara Therapeutics is a clinical-stage biotechnology startup focused on developing dual-action biologics. The business is developing bifunctional antibodies that are designed to deliver an immunomodulatory payload directly to the tumor microenvironment, assisting cancer patients in increasing immune cell activity and potentially providing long-term efficacy.
BICARA THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science Oncology Therapeutics
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.bicara.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
313 M USD
Technology used in webpage:
Euro CrUX Dataset CrUX Top 10m
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Surface Oncology
Surface Oncology develops next-generation cancer immunotherapy treatments based on proprietary discoveries.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Current Advisors List
Current Employees Featured
Investors List
F-Prime Capital
F-Prime Capital investment in Series C - Bicara Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Bicara Therapeutics
PremjiInvest
PremjiInvest investment in Series C - Bicara Therapeutics
Piper Heartland Healthcare Capital
Piper Heartland Healthcare Capital investment in Series C - Bicara Therapeutics
Bioqube Ventures
Bioqube Ventures investment in Series C - Bicara Therapeutics
Omega Funds
Omega Funds investment in Series C - Bicara Therapeutics
The Rise Fund
The Rise Fund investment in Series C - Bicara Therapeutics
Braidwell
Braidwell investment in Series C - Bicara Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Bicara Therapeutics
Eight Roads Ventures
Eight Roads Ventures investment in Series C - Bicara Therapeutics
Key Employee Changes
Official Site Inspections
http://www.bicara.com Semrush global rank: 4.75 M Semrush visits lastest month: 1.92 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bicara Therapeutics"
About - Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. โฆSee details»
Bicara Therapeutics - Crunchbase Company Profile
Bicara Therapeutics is a clinical-stage biotechnology startup focused on developing dual-action biologics. The business is developing bifunctional antibodies that are designed to deliver an immunomodulatory payload directly โฆSee details»
Bicara Therapeutics - LinkedIn
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators.See details»
Governance Overview โข Bicara Therapeutics Inc.
The Board of Directors of Bicara Therapeutics, Inc. (the โCompanyโ) sets high standards for the Companyโs employees, officers and directors. Implicit in this philosophy is the importance of โฆSee details»
Committee Composition โข Bicara Therapeutics Inc.
View the committee structure and board of director membership for Bicara Therapeutics Inc..See details»
SEC Filing โข Bicara Therapeutics Inc.
This is the initial public offering of shares of common stock of Bicara Therapeutics Inc. We are offering 17,500,000 shares of our common stock. Prior to this offering, there has been no โฆSee details»
Contact - Bicara Therapeutics
[email protected] 617-468-4219 [email protected] 116 Huntington Ave Suite 703 Boston, MA 02116See details»
Bicara Therapeutics - Funding, Financials, Valuation & Investors
Bicara Therapeutics is registered under the ticker NASDAQ:BCAX . Their stock opened with $18.00 in its Sep 13, 2024 IPO. Stock Symbol NASDAQ:BCAX ; Valuation at IPO $878.8M; โฆSee details»
Bicara Therapeutics - VentureRadar
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy and tumor modulators. Its bifunctional โฆSee details»
Bicara Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Bicara Therapeutics offering was the largest of that group, with $315 million in proceeds. Overall, its the most active two-month stretch for biotech IPOs since the start of the year, according to โฆSee details»
Bicara Therapeutics - Contacts, Employees, Board Members
Organization. Bicara Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of โฆSee details»
Press Releases โข Bicara Therapeutics Inc.
Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Jun โฆSee details»
Bicara Therapeutics Announces Closing of $362 Million Initial โฆ
Sep 16, 2024 Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicaraโs lead asset, โฆSee details»
Careers - Bicara Therapeutics
At Bicara, we are working towards a shared vision to provide first-in-class, meaningful new therapies to cancer patients. Our work requires us to be visionaries, leaders and achievers. โฆSee details»
SEC Filing โข Bicara Therapeutics Inc.
Nov 12, 2024 Bicara Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-42271 85-2903745 (State or other jurisdiction of. incorporation or organization) ...See details»
News - Bicara Therapeutics
Mar 1, 2024 Bicara in the news . All. Presentations & Publications. Poster Presentation: Updated dose expansion results of a Phase 1/1b study of the bifunctional EGFR/TGFฮฒ inhibitor โฆSee details»
Bicara Berita - Crunchbase Company Profile & Funding
Organization. Bicara Berita . Connect to CRM . Save . Summary. People. Signals & News. ... Bicara Berita is located in Depok, Jawa Barat, Indonesia. Unlock even more features with โฆSee details»
Patients - Bicara Therapeutics
Our Clinical Trials. Ficerafusp alfa (BCA101) is currently being evaluated in a dose expansion phase of an open-label Phase 1/1b clinical trial in combination with pembrolizumab in patients โฆSee details»
Science - Bicara Therapeutics
Mar 1, 2024 Ficerafusp alfa (BCA101) is a first-in-class, dual-action, bifunctional EGFR/TGF-ฮฒ antibody in clinical development for multiple different solid tumor cancer types.See details»